NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting
More than One-Third of Drug-Resistant Epilepsy Patients Achieved =90% Seizure Reduction with the RNS System.
NEW ORLEANS?American Epilepsy Society Annual Meeting, Booth 519 ? NeuroPace, Inc., a Silicon Valley-based medical technology company that recently launched the Next-Gen RNS? System for refractory epilepsy, today announced complete results from its groundbreaking Long-Term Treatment Study that prospectively evaluated 256 patients across 33 epilepsy centers with nearly 1,900 patient implant years of follow-up. Treatment with the RNS System, the world?s only brain-responsive neuromodulation system, resulted in significant seizure reduction and improved quality of life for patients, including improved memory and cognition1. Drug-resistant epilepsy patients in the study (who had a median of 10 seizures per month) experienced the following long-term clinical outcomes:
- Approximately 3 out of 4 patients responded to therapy, achieving at least 50% seizure reduction; 1 in 3 patients achieved at least 90% seizure reduction.
- 28% of patients experienced seizure-free periods of six months or longer and 18% experienced seizure-free periods of one year or longer.
- Median seizure reduction across all patients was 75% at 9 years.
- Quality of life improvements (including cognition) were sustained through 9 years, with no chronic stimulation-related side effects.
1Loring DW et al., Epilepsia, 2015
2Epilepsy Foundation. ?Facts about Seizures and Epilepsy.?
http://www.epilepsy.com/learn/epilepsy-101/facts-about-seizures-and-epilepsy
For Information
Adam Ouellet
MSL
781-684-0770
NeuroPace@mslgroup.com